

Francesca Sangalli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4024104/publications.pdf>

Version: 2024-02-01

29
papers

494
citations

759055

12
h-index

677027

22
g-index

30
all docs

30
docs citations

30
times ranked

1048
citing authors

#	ARTICLE	IF	CITATIONS
1	Stress related to COVID-19 pandemic as a trigger for disease activity in multiple sclerosis: a case report. <i>Neurological Sciences</i> , 2021, 42, 3969-3971.	0.9	3
2	Inferring Multiple Sclerosis Stages from the Blood Transcriptome via Machine Learning. <i>Cell Reports Medicine</i> , 2020, 1, 100053.	3.3	18
3	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. <i>Journal of the Neurological Sciences</i> , 2020, 417, 117064.	0.3	1
4	Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. <i>Neurological Sciences</i> , 2020, 41, 2843-2851.	0.9	7
5	High-dose steroid therapy for CNS inflammatory diseases increases INR in patients taking oral vitamin K antagonist. <i>Journal of Neurology</i> , 2019, 266, 3160-3161.	1.8	1
6	Loss of Circulating CD8+ CD161high T Cells in Primary Progressive Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 1922.	2.2	11
7	Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 75-77.	0.9	13
8	Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. <i>Annals of Neurology</i> , 2019, 85, 606-610.	2.8	30
9	Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. <i>Neurology</i> , 2019, 92, e733-e741.	1.5	57
10	Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 57-59.	0.9	1
11	Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients. <i>Journal of Neurology</i> , 2018, 265, 896-905.	1.8	12
12	Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod. <i>Neurological Sciences</i> , 2018, 39, 1467-1470.	0.9	10
13	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 447-453.	1.0	4
14	Digital epidemiology confirms a latitude gradient of MS in France. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 129-131.	0.9	6
15	Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood. <i>Journal of the Neurological Sciences</i> , 2018, 384, 58-60.	0.3	2
16	Dysregulation of MS risk genes and pathways at distinct stages of disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e337.	3.1	34
17	Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 454-461.	1.0	18
18	Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice. <i>Journal of the Neurological Sciences</i> , 2017, 383, 166-168.	0.3	29

#	ARTICLE	IF	CITATIONS
19	Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two cases. <i>Neurological Sciences</i> , 2017, 38, 361-364.	0.9	8
20	Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab. <i>Viruses</i> , 2016, 8, 128.	1.5	2
21	Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis. <i>Multiple Sclerosis International</i> , 2016, 2016, 1-9.	0.4	18
22	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 799-805.	2.4	13
23	Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 511-519.	1.4	76
24	Myeloid cells as target of fingolimod action in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e157.	3.1	26
25	Recurrence of disease activity after repeated Natalizumab withdrawals. <i>Neurological Sciences</i> , 2015, 36, 465-467.	0.9	11
26	Validation of 1-year predictive score of long-term response to interferon- β in everyday clinical practice multiple sclerosis patients. <i>European Journal of Neurology</i> , 2015, 22, 973-980.	1.7	16
27	Autologous Bone Marrow Transplantation for the Treatment of Multiple Sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 478.	2.0	24
28	Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 520-526.	0.9	34
29	Bilateral Intracavernous Carotid Artery Occlusion Caused by Invasive Lymphocytic Hypophysitis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 918.e9-918.e11.	0.7	9